UBS raised the firm’s price target on Penumbra (PEN) to $335 from $330 and keeps a Buy rating on the shares. Penumbra delivered another solid top- and bottom-line beat and sees the reiteration of U.S. thrombectomy guidance as largely predicated on weakness in U.S. Neuro and lack of visibility into market dynamics, the analyst tells investors in a research note. UBS continues to have high conviction in Penumbra.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PEN:
- Penumbra price target raised to $350 from $340 at Canaccord
- Penumbra, Inc. Reports Strong Q2 2025 Results
- Penumbra’s Promising Outlook: Buy Rating Amid Strong Performance and Strategic Growth Opportunities
- Closing Bell Movers: Qorvo, Starbucks jump after quarterly reports
- Penumbra raises FY25 revenue view to $1.355B-$1.370B from $1.34B-$1.36B